Collegium Pharmaceutical, Inc. COLL Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $193.52M-5.8% | $205.45M-1.9% | $209.36M+11.4% | $188M+5.8% | $177.76M-2.3% | ||
| $76.27M-1.0% | $77.07M-3.9% | $80.19M+0.7% | $79.62M-1.0% | $80.43M-3.9% | ||
| $117.25M-8.7% | $128.38M-0.6% | $129.17M+19.2% | $108.38M+11.4% | $97.32M-1.0% | ||
| 60.6%-1.9pp | 62.5%+0.8pp | 61.7%+4.0pp | 57.7%+2.9pp | 54.8%+0.7pp | ||
| $86.35M+27.7% | $67.64M+0.8% | $67.1M-8.9% | $73.64M-3.6% | $76.42M+21.1% | ||
| $86.35M+27.7% | $67.62M+0.8% | $67.08M-8.5% | $73.28M-3.1% | $75.64M+25.7% | ||
| $86.35M+27.7% | $67.62M+0.8% | $67.08M-8.5% | $73.28M-3.1% | $75.64M+25.7% | ||
| $30.9M-49.1% | $60.76M-2.1% | $62.09M+76.9% | $35.11M+61.9% | $21.69M-43.1% | ||
| 16%-13.6pp | 29.6%-0.1pp | 29.7%+11.0pp | 18.7%+6.5pp | 12.2%-8.7pp | ||
| $15.86M-17.8% | $19.29M-11.4% | $21.77M+6.4% | $20.46M-1.6% | $20.79M-8.2% | ||
| $3.71M+4.0% | $3.57M+14.4% | $3.12M+30.8% | $2.38M+7.1% | $2.23M+22.8% | ||
| $18.74M-35.5% | $29.04M-33.2% | $43.44M+155% | $17.03M+445% | $3.12M-81.9% | ||
| $4.24M-64.8% | $12.07M+1.2% | $11.93M+137% | $5.04M+615% | $705K-85.1% | ||
| $14.5M-14.5% | $16.96M-46.2% | $31.51M+163% | $11.98M+396% | $2.42M-80.7% | ||
| 7.5%-0.8pp | 8.3%-6.8pp | 15%+8.7pp | 6.4%+5.0pp | 1.4%-5.5pp | ||
| $0.40-13.0% | $0.46-45.2% | $0.84+147% | $0.34+386% | $0.07-80.6% | ||
| $0.45-16.7% | $0.54-46.0% | $1.00+163% | $0.38+375% | $0.08-79.5% | ||
| 40.1M0.0% | 40.1M+1.6% | 39.4M+0.9% | 39.1M+19.0% | 32.8M-18.1% | ||
| 32.1M+1.4% | 31.7M+0.3% | 31.6M-0.8% | 31.8M+0.1% | 31.8M-0.9% | ||
| $55.47M— | —— | —— | —— | $55.47M+34.2% | ||
| $0+100% | -$19K0.0% | -$19K+94.7% | -$358K+54.5% | -$786K+73.0% | ||
| $3.71M+4.0% | $3.57M+14.4% | $3.12M+30.8% | $2.38M+7.1% | $2.23M+22.8% | ||
| $193.52M-5.8% | $205.45M-1.9% | $209.36M+11.4% | $188M+5.8% | $177.76M-2.3% | ||
| $30.9M-49.1% | $60.76M-2.1% | $62.09M+76.9% | $35.11M+61.9% | $21.69M-43.1% | ||
| $86.83M+40.8% | $61.68M-2.3% | $63.12M+74.2% | $36.24M-53.7% | $78.25M-17.3% | ||
| $86.83M+40.8% | $61.68M-2.3% | $63.12M+74.2% | $36.24M-53.7% | $78.25M-17.3% | ||
| 44.9%+14.8pp | 30%-0.1pp | 30.1%+10.9pp | 19.3%-24.7pp | 44%-8.0pp | ||
| $30.9M-49.1% | $60.76M-2.1% | $62.09M+76.9% | $35.11M+61.9% | $21.69M-43.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s revenue?
- Collegium Pharmaceutical, Inc. (COLL) generated $796.3M in revenue over the trailing twelve months, up 19.9% year over year.
- Is Collegium Pharmaceutical, Inc. profitable?
- Collegium Pharmaceutical, Inc. reported $74.9M in net income over the trailing twelve months, a 9.4% net margin.
- What are Collegium Pharmaceutical, Inc.'s profit margins?
- Gross margin is 60.7% and operating margin is 23.7%, with a 9.4% net margin.
- What is Collegium Pharmaceutical, Inc.'s earnings per share?
- Collegium Pharmaceutical, Inc.'s diluted EPS over the trailing twelve months is $2.04.
- Where does Collegium Pharmaceutical, Inc.'s income statement data come from?
- Every line is extracted from Collegium Pharmaceutical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
